Real-World study tests migraine Pill's consistency and satisfaction
NCT ID NCT06467370
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study follows adults with migraine who have been prescribed rimegepant (a dissolving tablet) for acute attacks. Researchers want to see how consistently the drug provides meaningful pain relief across multiple attacks and how satisfied people are with it. The study also looks at whether rimegepant works well for those already taking other migraine preventives like CGRP antibodies or Botox. Participants track their symptoms and relief in a daily diary over 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rimegepant (oral dissolving tablet)
What this could lead to
If successful, this study could show how reliably rimegepant eases migraine attacks in real-world use, especially for people also taking other preventives.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient expectations or other treatments. It does not test a new drug or compare rimegepant to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States